Restless Legs Syndrome - Recognition Lacking Still

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2004-11-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Although there are a huge number of individuals who report having the symptoms of RLS, this neurological disorder remains inadequately diagnosed and treated. There are plenty of opportunities in this market for pharmaceutical manufacturers, but raising awareness must be the first priority.


Scope

  • Overview of the epidemiology and size of the RLS patient population
  • Examination of current clinical practice including professional involvement, clinical guidelines, and current treatment strategies
  • Evaluation of the market potential of key compounds, such as ropinirole and rotigotine, currently in development for restless legs syndrome
  • Assessment of key unmet needs in the restless legs market and strategies for addressing these


    • Report Highlights
    Despite affecting an estimated 66.6 million individuals, less than 10% of RLS sufferers receive treatment. If market entrants plan to see a return on their investment, raising awareness amongst the public and physicians is key.

    At present, there is no treatment approved for RLS in the US and therapy typically involves 'off-label' use of a variety of drug classes. GSK's Requip is expected to be first to market during 2005 and will receive a significant boost to its revenues.

    Companies entering the market after Requip may have to implement more innovative strategies, such as targeting specific symptoms and patient cohorts, if they are to gain support from regulatory bodies and physicians.


    Reasons to Purchase

  • Assess the potential size of the restless legs syndrome patient population
  • Identify current therapies used for restless legs syndrome and the key unmet needs
  • Benchmark pipeline products against currently used therapies and assess future market potential

    • Table of Contents

    Other users found this report page using the following search terms: rls restless leg syndrome restless requip syndrome market leg morepractice_guidelines legs mirapex rls size

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.